Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kevin Grogan

Managing Editor

London, UK
Set Alert for Articles By Kevin Grogan

Latest From Kevin Grogan

Bayer's Weinand On Pricing, Payers And Pipelines

Bayer's pharma president and board member Dieter Weinand talks to Scrip about the importance of big picture thinking when weighing the value of innovative drugs to healthcare systems, the revolutionary potential of big data and how "transparency and open dialogue will further enhance the understanding of our business."

Scrip 100 Pricing Debate

Family Comes First as BI Finance Chief Exits Over Future Direction

The departure of finance chief Simone Menne follows "divergent views" with the board over strategy shows that Boehringer Ingelheim will not countenance any moves that could threaten its independence.

Leadership Business Strategies

Interview: Actelion CEO Aims To Drive 'Small Big Company' To Greater Growth In J&J

Jane Griffiths tells Scrip that rather than reducing Actelion's reliance on PAH, there is still a lot to do in looking at different mechanisms and pathways for the disease and being under the J&J umbrella can only help.

Leadership M & A

Interview: GW Pharma Gears Up For Pivotal 2018

The UK group has raised nearly $320m this week which will be used to build commercial organizations in the US and Europe ahead of potential approvals for its cannabinoid epilepsy therapy Epidiolex.

Neurology Pediatrics

Shire Explores Robotic Pill Potential For Hemophilia

The company has linked up with Rani Therapeutics to develop a simple-to-swallow capsule that is able to provide an alternative to current injectable therapies for hemophilia A.

Deals Blood & Coagulation Disorders

Canny Clozel Gets Another $230m From J&J For Idorsia Hypertension Drug

Idorsia, the Swiss company spun out of Actelion after the latter was bought by J&J, is to get another windfall from the US major which has triggered an option to co-develop the Phase III-ready drug aprocitentan.

Cardiovascular Deals
See All